

# Intravitreal Triamcinolone with Transpupillary Thermal Therapy (TTT) for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration

<b>Submission date</b> 09/05/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 16/05/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 18/02/2008	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Ricardo Agurto-Rivera

**Contact details**  
Exequiel Fernández n° 920  
Casa F  
Ñuñoa  
Santiago  
Chile  
+56 8 5021968  
ricardo\_agurto@yahoo.com

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

## Secondary identifying numbers

N/A

# Study information

## Scientific Title

### Study objectives

TTT plus intravitreal triamcinolone are effective treatment for choroidal neovascularization and are better than TTT alone.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Not provided at time of registration

### Study design

Randomised controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

## Participant information sheet

### Health condition(s) or problem(s) studied

Age-Related Macular Degeneration (ARMD) not available for current therapies

### Interventions

Complete ophthalmologic examination, treatment with TTT alone compared with treatment with TTT plus intravitreal Triamcinolone. Ophthalmologic control to verify closure of CNV or re-treatment.

### Intervention Type

Drug

### Phase

Not Specified

### Drug/device/biological/vaccine name(s)

Triamcinolone

**Primary outcome measure**

Preservation of visual acuity

**Secondary outcome measures**

Closure of CNV, OCT characteristics

**Overall study start date**

01/02/2004

**Completion date**

28/02/2006

## **Eligibility**

**Key inclusion criteria**

Patients with severe ARMD (choroidal neovascularization [CNV]) that could not be treated with photodynamic therapy (PDT) because of bad prognosis or economical reasons.

**Participant type(s)**

Patient

**Age group**

Not Specified

**Sex**

Not Specified

**Target number of participants**

200

**Key exclusion criteria**

1. Any patient that has indication for PDT and has the economical means to get this therapy
2. Media opacity
3. Previous treatment for CNV

**Date of first enrolment**

01/02/2004

**Date of final enrolment**

28/02/2006

## **Locations**

**Countries of recruitment**

Chile

Mexico

**Study participating centre**  
**Exequiel Fernández nº 920**  
Santiago  
Chile

## **Sponsor information**

### **Organisation**

Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)

### **Sponsor details**

Vicente García Torres N° 46  
Barrio San Lucas  
Del Coyoacán  
Mexico City  
Mexico  
04030  
+52 10841400  
retinamex@yahoo.com

### **Sponsor type**

Not defined

### **ROR**

<https://ror.org/03sgfhr82>

## **Funder(s)**

### **Funder type**

Charity

### **Funder Name**

Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)

## **Results and Publications**

### **Publication and dissemination plan**

Not provided at time of registration

### **Intention to publish date**

# Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	25/11/2005		Yes	No